NEW YORK (GenomeWeb News) – Warnex Medical Laboratories has licensed from Xenomics the rights to use a marker for acute myeloid leukemia in a diagnostic test, Xenomics said Thursday.

The agreement gives Warnex nonexclusive rights in Canada to use a recently discovered mutation in the NPM1 gene in a lab service to help doctors diagnose, stratify, and monitor AML patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.